XNAS · Healthcare · Biotechnology
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | Q1 2026 | -1.87 | -4.50 | -140.64% | $0 | ❌ Miss | -4.69% | -19.77% | — |
| 2026-04-10 | Q4 2025 | -2.10 | -7.60 | -261.90% | $0 | ❌ Miss | -12.99% | +0.51% | -9.02% |
| 2025-11-12 |
| Q3 2025 |
| -0.21 |
| -0.25 |
| -19.05% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-11 | Q2 2025 | -0.25 | -0.34 | -36.00% | $0 | ❌ Miss | +1.88% | +4.38% | +0.63% |
| 2025-03-24 | Q4 2024 | -0.10 | -0.28 | -180.00% | $0 | ❌ Miss | -2.14% | -5.00% | -24.29% |
| 2024-11-13 | Q3 2024 | — | -0.13 | — | $0 | — | +19.50% | +15.72% | +27.67% |
| 2024-08-13 | Q2 2024 | — | -0.19 | — | $0 | — | -4.55% | +5.92% | +27.63% |
| 2024-05-13 | Q1 2024 | — | -0.26 | — | $0 | — | -1.05% | -2.16% | -22.26% |
Showing last 8 quarters.